Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LENZ Submits NDA to FDA for LNZ100 to Treat Presbyopia
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Product Name : LNZ100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2024
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CORXEL And LENZ Report Phase 3 Data for Presbyopia Drug LNZ100
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Product Name : LNZ100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2024
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LENZ Gets FDA Acceptance for LNZ100 NDA for Presbyopia Treatment
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Product Name : LNZ100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ridgeback Capital
Deal Size : $30.0 million
Deal Type : Private Placement
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
Details : The net proceeds will be used to fund the clinical advancement of LNZ100 (aceclidine & brimonidine tartrate), which is being evaluated in the late-stage clinical trial for the treatment of Presbyopia.
Product Name : LNZ100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 15, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ridgeback Capital
Deal Size : $30.0 million
Deal Type : Private Placement
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Graphite Bio
Deal Size : Undisclosed
Deal Type : Merger
LENZ Completes Merger with Graphite Bio and Provides Clinical and Corporate Update
Details : The collaboration will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free eye drops containing aceclidine and aceclidine plus brimonidine for presbyopia treatment.
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 21, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Graphite Bio
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Details : LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Sectoral Asset Management
Deal Size : $83.5 million
Deal Type : Series B Financing
Details : The Proceeds will enable LENZ to complete the development and registration and, pending approval, launch LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine) in the United States.
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 03, 2023
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Sectoral Asset Management
Deal Size : $83.5 million
Deal Type : Series B Financing
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Both LNZ100 (aceclidine), and LNZ101 (aceclidine + brimonidine) maintained statistical significance of three-line or greater improvement compared to vehicle for all timepoints including the last measured at 10 hours, 37% and 48% respectively.
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Ji Xing Pharmaceuticals
Deal Size : $110.0 million
Deal Type : Licensing Agreement
Details : Under the license agreement with Ji Xing Pharmaceuticals, LENZ will develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China.
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
April 13, 2022
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Ji Xing Pharmaceuticals
Deal Size : $110.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : RTW Investments
Deal Size : $10.0 million
Deal Type : Financing
Details : The investment by RTW promise LENZ to emerge as a global leader based on its potential best-in-class aceclidine presbyopia eye drop. Aceclidine is a small molecule acetylcholine receptor agonist that causes pupil contraction, creating pinhole effect that...
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 13, 2022
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : RTW Investments
Deal Size : $10.0 million
Deal Type : Financing